	US 12,325,747 B2
	Human PD-L1 antibodies and methods of use therefor
Michael A. Curran, Houston, TX (US); Carlo Toniatti, Houston, TX (US); Ashvin R. Jaiswal, Houston, TX (US); Dongxing Zha, Houston, TX (US); Kui Voo, Houston, TX (US); Bianka Prinz, Lebanon, NH (US); and Nadthakarn Boland, Lebanon, NH (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Nov. 17, 2022, as Appl. No. 18/056,711.
Application 18/056,711 is a continuation of application No. 16/754,852, granted, now 11,525,002, previously published as PCT/US2018/055261, filed on Oct. 10, 2018.
Claims priority of provisional application 62/647,442, filed on Mar. 23, 2018.
Claims priority of provisional application 62/571,066, filed on Oct. 11, 2017.
Prior Publication US 2024/0043538 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G01N 33/543 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 39/395 (2013.01); A61P 35/00 (2018.01); G01N 33/54306 (2013.01); A61K 2039/505 (2013.01)]

11 Claims

1. A method of treating a subject having breast cancer, colorectal cancer or ovarian cancer comprising delivering to said subject an antibody or antibody fragment having heavy chain CDR1-3 of SEQ ID NOS: 22, 23 and 24, and light chain CDR1-3 of SEQ ID NOS: 37, 38 and 39.